Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage

Sun Pharmaceutical Industries Limited and Israel-based Moebius Medical Limited have announced the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). The articles highlight MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis. The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial, demonstrating that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks. The second publication details MM-II’s unique mechanism of action, showing that it forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. New data on MM-II will be presented at the OARSI 2025 World Conference on Osteoarthritis. MM-II has been granted Fast Track Designation by the US FDA.